Skip to main content
  • Bal Pharma Ltd launch of Favipiravir formulation into Indian market, under the brand name BALflu

    Bal Pharma Ltd is pleased to announce the launch of Favipiravir formulation into Indian market, under the brand name BALflu.

  • Olympus Acquires Israeli Medical Device Company Medi-Tate to Drive Global Urology Business Growth

    Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the minimally invasive treatment of BPH. The company’s flagship product iTind has received U.S. FDA de Novo authorization and a European CE mark. With its initial Medi-Tate investment, Olympus has had the right of distribution since November 2018.

  • Webinar on Testing Protocols & Stability Studies of AYUSH Products

    “In Testing Protocols, Shelf life studies & date of expiry have been made mandatory for the licensing of ASU drugs by Dr. J.L.N Sastry, CEO, National Medicinal Plants Board, Ministry of AYUSH, Govt. of India”

    AYUSH Committee, PHD Chamber organized a webinar on “Testing Protocols & Stability Studies of AYUSH Products” on 27th May 2021.

  • BRICS meeting deliberated on emerging issues in Biotechnology and Biomedicine

    Experts deliberated on emerging issues in the various fields of Biotechnology and Biomedicine at the fourth BRICS Working Group meeting on the subject area.

    More than 60 participants, including researchers, academicians, and government officials participated from all five BRICS countries Brazil, Russia, India, China, and South Africa, participated in the online meeting organized from May 25 to May 26 2021.

  • Lupin Announces Achievement of Key Milestones for its Clinical Stage MEK Inhibitor Compound

    Lupin Limited announced the achievement of key milestones for Lupins MEK inhibitor compound (LNP3794) that is planned for development by Boehringer Ingelheim in combination as potential targeted therapy for patients with difficult-to-treat cancers.

    As part of the agreement, Lupin has received payment of USD 50 million from Boehringer Ingelheim
    for achievement of key milestones.

  • Roche Antibody Cocktail of Casirivimab and Imdevimab is now available in India

    Roche India and Cipla Limited announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients. Cipla will distribute the product by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and COVID treatment centers.

  • Zydus launches Trastuzumab for Breast Cancer treatment

    Zydus Cadila, a global innovation driven healthcare company, launched Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar and a highly effective drug for treating both Early and Advanced HER2 positive Breast Cancer, under the brand name Ujvira. HER2 positive Breast Cancer is considered an aggressive form and constitutes 20 to 25% of all Breast Cancers.

  • Glenmark Pharmaceuticals receives ANDA approval for Icatibant Injection

    Glenmark Pharmaceuticals Limited has received final approval by the United States Food & Drug Administration (U.S. FDA) for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, the generic version of Firazyr Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, of Shire Human Genetic Therapies, Inc. This marks Glenmark’s first synthetic decapeptide injectable approval and will be manufactured in their North American manufacturing facility based in Monroe, North Carolina.

  • Roche Tecentriq helps certain people with early lung cancer live

    Roche announced interim results from the Phase III IMpower010 study, showing for the first time that treatment with Tecentriq (atezolizumab) following surgery and chemotherapy reduced the risk of disease recurrence or death (disease-free survival; DFS) by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50–0.88) in people with Stage II-IIIA non-small cell lung cancer (NSCLC), whose tumours express PD-L1≥1%, compared with best supportive care (BSC). In this population, median DFS was not yet reached for Tecentriq compared with 35.3 months for BSC.

  • RYBREVANT got FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer

    The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Subscribe to Pharma News

Search this website